Evaluation of a male-specific psychotherapeutic program for depression
Official title: Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders Compared to Standard Cognitive Behavioral Therapy: a Randomized Controlled Superiority Trial
Run by University of Zurich · NCT05435222 · Data updated 2026-11-12
This study is testing a new therapy program designed specifically for men with depression to see if it works better than standard therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 50 Years |
| Sex | Men only |
| Enrollment | 244 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Status | Recruiting |
| Started | March 15, 2023 |
| Main results expected | October 1, 2025 |
| Study ends | October 31, 2025 |
| Registry record updated | March 28, 2025 |
| Trial ID | NCT05435222 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are German-speaking men aged 25 to 50 currently experiencing major depression.
✕Probably not a fit
Patients with prior hormonal treatment, severe physical disorders, or other significant psychological disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project evaluates a male-specific psychotherapeutic program (MSPP) designed for men suffering from major depressive disorder (MDD). The study involves 144 depressed men aged 25 to 50, who will be randomized into three groups: those receiving the MSPP, standard cognitive behavioral therapy (CBT), or placed on a waitlist. The program consists of 18 weekly sessions, and participants will undergo clinical assessments and biosampling at various intervals. The aim is to determine if the MSPP is more effective than standard CBT in treating MDD in men, particularly considering their unique psychological needs.
Why it matters
Potential benefit: If successful, this program could provide a tailored therapeutic approach that encourages more men to seek and engage in effective treatment for depression.
How similar studies have gone: While traditional CBT has been widely studied, the male-specific approach of this program is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Male sex
2. Age between 25 - 50 years
3. German speaking
4. Current major depression (assessed by SCID-5)
5. Informed consent as documented by signature
Exclusion Criteria:
1. Inability to give informed consent
2. Prior hormonal (testosterone) treatment
3. Prior mental health disorder
4. Current or previous psychopharmacological treatment
5. Current or previous psychological treatment for any psychological disorder
\- Exception for persistent depressive disorder (Dysthymia) and alcohol/substance use disorder of mild degree (SCID-5, 1 - 3 criteria met)
6. Comorbidities of major depression with any other psychological disorder
7. Severe physical disorder that requires priority treatment
8. Any of the following physical conditions, particularly relevant in regard to testosterone treatment:
* Diagnosed prostate cancer
* Prostatic intraepithelial neoplasia (PIN)
* Severe lower urinary tract symptoms
* Erythrocytosis Sleep apnea, diagnosed but untreated
9. Current treatment with:
* Thyroid hormones
* Finasteride
* Antiepileptic drugs
* Anabolic compounds
* Hypnotic medication more than 2 nights/week for the treatment of insomnia
* Long-acting benzodiazepines
* Antipsychotic medication
* Drugs that affect serum testosterone
10. Genetic / hormonal disorders:
* Klinefelter's syndrome
* Cushing's disease
* Addison's disease
* Hashimoto Thyroiditis
Where it's running
-
Ambulatory for Cognitive Behavioral Therapy and Behavioral Medicine of the University of Zurich
Zurich, Canton of Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Andreas Walther, PhD — University of Zurich
- Study coordinator: Andreas Walther, PhD
- Email: a.walther@psychologie.uzh.ch
- Phone: +41 78 307 18 16
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dupilumab for Major Depressive Disorder
This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.
-
Accelerated vs Standard iTBS for Major Depression
This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.
-
Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD
This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.
-
Magnesium Bisglycinate Added to Your Depression Treatment
This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.
-
Motif XCS System for treatment-resistant depression
This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.
-
A Phase 3 test of DT120 for major depressive disorder
DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.